Targeting MSR1 using monoclonal antibody therapy in an obesity-associated NAFLD mouse model and human liver slices displayed prevention of foamy macrophage formation and inflammation by regulating the JNK signaling pathway (150). Here, MSR1 is linked to metabolic dysfunction-associated steatotic liver disease.